PK, PD and Safety of Tegoprazan 12.5 mg After Oral Administration in Healthy Subjects
Status:
ENROLLING_BY_INVITATION
Trial end date:
2024-07-31
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to explore pharmacokinetics, pharmacodynamics, and safety of tegoprazan 12.5 mg in healthy subjects when orally administered as a single dose or as multiple doses twice daily.